Advertisement

Fundamentals of Platelet and Granulocyte Support in Myelosuppressed Leukemia and Bone Marrow Transplant Patients

  • J. P. Hester
  • R. Ayyar
  • M. Keating
  • K. Dicke
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 10)

Abstract

The basic objective of platelet replacement is to provide hemostasis for patients with inadequate bone marrow function who are at risk for major and/or fatal hemorrhage from thrombocytopenia. The degree of physiologic deficit generally accepted to correlate with an increased risk of hemorrhage is a peripheral blood platelet concentration < 20x109/l. In general, a normal template bleeding time is believed to reflect in vivo hemostasis. The fundamental task would appear to be to: 1) establish the relationship between peripheral blood platelet concentration and a normal bleeding time; and 2) define the total dose of cells required to achieve this concentration. The intravascular survival of the transfused platelets would then determine the frequency of replacement and the duration of myeolosuppression would define the total number of transfusions required. However, biologic systems do not lend themselves to such simple solutions and complications in interpretation of transfusion results occur from numerous patient and component variables. Transfusion response is altered by numerous clinical variables which may occur as single events or combinations of events. Issues related to the component include the selection of pooled units of platelet concentrates versus single donor, and fresh versus stored platelets. Issues relating to granulocyte concentrates include all those enumerated for platelet replacement, but introduce unresolved questions of identifying patients whose infections will not be controlled by antibiotics alone and defining response criteria.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mollison PL. Blood transfusion in clinical medicine. London: Blackwell Scientific, 1983: 99–128.Google Scholar
  2. 2.
    Simon TL, Nelson EJ, Carmen R, Murphy S. Extension of platelet concentrate storage. Transfusion 1983; 23: 207–12.PubMedCrossRefGoogle Scholar
  3. 3.
    Buchholz DH, Porten JH, Menitove JE, et al. Description and use of the CS-3000 blood cell separator for single donor platelet collection. Transfusion 1983; 23: 190–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Hester JP, McCredie KB, Freireich EJ. Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients. Transfusion 1982; 22: 305–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Roper PR. The relationship between age, volume, and function in the human platelet population. A dissertation for the degree of Doctor of Philosophy, The University of Texas Health Science Center at Houston, 1978.Google Scholar
  6. 6.
    Estey E, Keating MJ, Body GP, McCredie KB, Freireich EJ. Causes of failure of remission induction in actue myelogenous leukemia (AML). Proc Amer Soc Clin Oncol 1980; 21: 436.Google Scholar
  7. 7.
    Gaydos LA, Freireich EJ, Mantel N. The quantitative relationship between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962; 266: 905–9.PubMedCrossRefGoogle Scholar
  8. 8.
    Djerassi I, Farber S. Control and prevention of hemorrhage: Platelet transfusion. Cancer Res 1964; 25: 1499–504.Google Scholar
  9. 9.
    Aster R. Effect of anticoagulant and ABO compatibility on recovery of transfused human platelets. Blood 1965; 26: 732–44.PubMedGoogle Scholar
  10. 10.
    Yankee RA. Importance of histocompatibility in platelet therapy. Vox Sang 1971; 20: 419–26.PubMedCrossRefGoogle Scholar
  11. 11.
    Duquesnoy RJ, Filip DJ, Aster RH. Influence of HLA-A2 on the effectiveness of platelet transfusions in alloimmunized thrombocytopenic patients. Blood 1977; 50: 407–12.PubMedGoogle Scholar
  12. 12.
    Aster RH. Matching of blood platelets for transfusion. Am J Hemat 1978; 5: 373–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Schiffer CA, Keller C, Dutcher JP, Aisner J, Hogge D, Wiernik PH. Potential HLA-matched platelet donor availability for alloimmunized patients. Transfusion 1983; 23: 286–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Schiffer CA, Slichter SJ. Platelet transfusions from single donors. N Engl J Med 1982; 307: 245–6.PubMedCrossRefGoogle Scholar
  15. 15.
    Graw RG, Herzig G, Henderson PS. Normal granulocyte transfusion therapy. Treatment of septicemia due to gram negative sepsis. N Engl J Med 1972; 287: 367.PubMedCrossRefGoogle Scholar
  16. 16.
    McCredie KB, Freireich EJ, Hester JP, Vallejos C. Leukocyte transfusion therapy for patients with host-defense failure. Transplant Proc 1973; 5: 1285–9.PubMedGoogle Scholar
  17. 17.
    Vogler WR, Winton EF, Larson DH. Methods of collection and results of transfusion of granulocytes. Exp Hematol 1978; 6: 93.Google Scholar
  18. 18.
    Strauss RG, Connett JE, Gale RP, et al. A controlled trial of prophylactic granulocyte transfusions during initial induction chemotherapy for acute myelogenous leukemia. N Engl J Med 1981; 305: 597–603.PubMedCrossRefGoogle Scholar
  19. 19.
    Winston DS, Ho WG, Young LS. Prophylactic granulocyte transfusions during human bone marrow transplantation. Am J Med 1980; 68: 893–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Mishler JM, Hester JP, Huestis D, Rock G, Strauss RG. Dosage and scheduling regimens for erythrocyte sedimenting macromolecules. J Clin Apheresis. In press, 1983.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1984

Authors and Affiliations

  • J. P. Hester
  • R. Ayyar
  • M. Keating
  • K. Dicke

There are no affiliations available

Personalised recommendations